Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.1552W HIGH $43.85
Volume
499.98 K
Value Traded
3.47 M
Short % Float
14.45%
-0.2%Week
-16.54%1 Month
-48.47%3 Month
-40.76%6 Month
-86.3%5 Year
-83.09%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
254.02 M
EPS (TTM)
-10.89
P/E Ratio
-
Ent. Value
89.68 M
Total Shares
16.59 M
Float Shares
14.37 M
Insiders
13.34%
Institutions
87.72%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
STRO Catalyst Timeline
Dated clinical, regulatory and corporate events for Sutro Biopharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sutro Biopharma, Inc.
424Total events
19Upcoming
56Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Lucas Donigian appointed Senior Vice President, Business Development
▲Topline ReadoutSTRO-004Clinical Data
Early safety and clinical activity data from STRO-004 Phase 1 study
advanced solid tumorssource ↗
●Dose Finding UpdateSTRO-004Trial
Dose optimization ongoing between 4-5 mg/kg
advanced solid tumorssource ↗
▲Interim Efficacy DataSTRO-004Clinical Data
Early clinical activity including confirmed and ongoing unconfirmed partial responses
advanced solid tumorssource ↗
▲Safety Data UpdateSTRO-004Clinical Data
Favorable tolerability profile with mostly low-grade AEs
advanced solid tumorssource ↗
▲PK PD DataSTRO-004Clinical Data
Predictable PK with dose-proportional exposures and half-life of nearly seven days
advanced solid tumorssource ↗
▲Enrollment MilestoneSTRO-004Trial
Initial dose escalation cohorts enrolled within 7 months
advanced solid tumorssource ↗
▲Enrollment MilestoneSTRO-004Trial
Rapid enrollment of initial dose escalation cohorts within 7 months
advanced solid tumorssource ↗
◆Topline ReadoutSTRO-004Clinical Data
Initial safety, PK and early activity data from Phase 1 dose-escalation trial of STRO-004
advanced solid tumorssource ↗
▲Enrollment MilestoneSTRO-004Trial
Initial dose escalation cohorts enrolled within 7 months
advanced solid tumorssource ↗
▼Equity OfferingCorporate
Underwritten offering of 7,868,383 shares at $13.98 per share, gross proceeds $110M
▲Oral PresentationSTRO-004Presentation
Oral presentation of STRO-004 preclinical data at AACR 2026
TF-expressing solid tumorssource ↗
▲Poster PresentationSTRO-006Presentation
Poster presentation of STRO-006 preclinical data at AACR 2026
solid tumorssource ↗
▲Poster PresentationSTRO-227Presentation
Poster presentation of STRO-227 preclinical data at AACR 2026
solid tumorssource ↗
▲Oral PresentationASP2998Presentation
Oral presentation of ASP2998 preclinical data at AACR 2026 by Astellas
TROP2-expressing tumorssource ↗
●Oral PresentationSTRO-004Presentation
Oral presentation on STRO-004 at AACR 2026
TF-expressing solid tumorssource ↗
●Oral PresentationASP2998Presentation
Oral presentation on ASP2998 at AACR 2026
TROP2-expressing tumorssource ↗
◆Topline ReadoutSTRO-004Clinical Data
Initial clinical data expected mid-2026
TF-expressing solid tumorssource ↗
▲First Patient DosedASP2998Trial
First patient dosed in Astellas' TROP2-targeted iADC program (ASP2998)
TROP2-expressing tumorssource ↗
▲Enrollment CompleteSTRO-004Trial
Completed dosing across three cohorts in Phase 1 trial of STRO-004
Tissue Factor (TF) expressing tumorssource ↗
▲First Patient DosedTrial
Patient dosing commenced for Astellas-partnered iADC dual-payload program
Cancersource ↗
▼Program DiscontinuationluveltaDiscontinuedCorporate
Luvelta program closed; no additional investment
▼Equity OfferingCorporate
Pricing of $110.0 million underwritten offering of common stock at $13.98 per share
▲First Patient DosedSTRO-004Trial
Phase 1 trial ongoing; dose level 2 cleared, cohort 3 dosed as of February 2026
solid tumorssource ↗
◆Oral PresentationPresentation
Sutro Biopharma to present at 44th Annual J.P. Morgan Healthcare Conference
▲First Patient DosedASP2998Trial
ASP2998 entered clinic and actively dosing patients
TROP2-expressing tumorssource ↗
◆Trial InitiationTrial
First iADC program from Astellas collaboration expected to enter clinic in early 2026
cancersource ↗
◆First Patient DosedSTRO-004Trial
First patient dosed in first-in-human basket trial for STRO-004
Tissue Factor-positive tumorssource ↗
▲First Patient DosedSTRO-004Trial
First cohort of patients dosed in Phase 1 trial of STRO-004
TF-expressing solid tumorssource ↗
▼Restructuring LayoffsCorporate
Organizational headcount reduction by nearly 50% and decommissioning of manufacturing facility by year-end 2025
●Development Candidate NominationSTRO-227Preclinical
PTK7 selected as target for first dual-payload candidate STRO-227
cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How STRO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-01 | STRO-004 (TF-targeting exatecan ADC) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$47M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.2x
rNPV / MCap
Top 61%
Micro Cap(rank 402 of 658)
Percentile Rank
Sutro Biopharma, Inc. faces pipeline headwinds (33/100), with $595M risk-adjusted pipeline value, led by STRO-004 in Head and Neck Squamous Cell Carcinoma HNSCC (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STRO-004 Small moleculeNCT07227168 | Head and Neck Squamous Cell Carcinoma HNSCC | Phase 1 | RECRUITING | 200 | Apr 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every STRO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| luveltamab tazevibulin Fast TrackOrphanRare Pediatric | late-stage ovarian cancer | Phase 1b | 2024-09-14 | 56%; 35%; 9.3 months; 44%; 29%Read More | Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gerber Hans-PeterOfficer (CHIEF SCIENTIFIC OFFICER) | Option | 3,750 13,712 held | $0.00 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in STRO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.7 % (133.3 %) | 43.32 M | 1.30 M | 82.42% ( 589.54 K) |
STRO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How STRO ranks across every disease it competes in
Competitive Position is a premium feature
See how STRO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSTRO News
STROSutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Sutro Biopharma has appointed Lucas Donigian as Senior Vice President of Business Development, effective September 28, 2026. With over 20 years of experience in biotechnology, Donigian is expected to leverage his expertise to enhance Sutro's strategic partnerships and advance its antibody-drug conjugate pipeline. The company is optimistic about its ongoing clinical trials and future opportunities.
Read more →STRO▼ -14.9%on this news
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Sutro Biopharma reported positive early results from its STRO-004 Phase 1 study, showing encouraging clinical activity and a favorable safety profile. The study has rapidly enrolled patients and is currently optimizing dosing. Additionally, the company has a strong financial position with significant cash reserves, supporting future clinical developments.
Read more →STROSutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026
Sutro Biopharma reported financial results for Q1 2026, highlighting progress in its clinical and preclinical pipeline. The company anticipates initial safety and pharmacokinetic data from the Phase 1 trial of STRO-004 by mid-2026. Further advancements include the STRO-006 and STRO-227 ADC candidates, with IND submissions planned for 2026. Sutro's collaboration with Astellas has led to the first dual-payload iADC entering the clinic, reinforcing the company's commitment to developing innovative cancer therapies.
Read more →STROAACR Annual Meeting 2026 – Presentation and Posters
At the AACR Annual Meeting 2026, Sutro Biopharma presented several promising findings related to their investigational therapies. Notably, STRO-004 demonstrated superior efficacy in treating TF-expressing solid tumors. Additionally, a Phase 1 study highlighted its safety and preliminary anti-tumor activity. Other presentations included advancements in dual-payload antibody-drug conjugates targeting various cancer mechanisms.
Read more →STRO▲ +9.6%on this newsshared move
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
Sutro Biopharma presented promising preclinical data on its ADC pipeline at the AACR Annual Meeting 2026. Notably, STRO-004 exhibited significant antitumor activity in various solid tumor models, outperforming benchmark ADCs. The company also highlighted its collaboration with Astellas on the TROP2-targeted iADC program, showcasing the potential of dual-payload ADCs in cancer therapy.
Read more →STRO▲ +10.5%on this news
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Sutro Biopharma reported its financial results for 2025, highlighting significant advancements in its clinical trials and pipeline. The company has completed dosing for three cohorts in the Phase 1 trial of STRO-004, with initial data expected in mid-2026. Additionally, Sutro is accelerating its dual-payload program STRO-227 and has commenced patient dosing in collaboration with Astellas Pharma. Financially, Sutro maintains a strong position with $141.4 million in cash, extending its runway into 2028.
Read more →STRO16th Annual World ADC London Summit – Presentation
The 16th Annual World ADC London Summit featured a presentation by Dr. Hans-Peter Gerber, focusing on the efficacy and safety profiles of dual payload antibody-drug conjugates (ADCs). The presentation emphasized novel linker payloads designed to overcome resistance mechanisms in cancer treatment. This innovative approach showcases advancements in ADC technology.
Read more →STROSutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma, a clinical-stage oncology company, announced its participation in several upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference. The company is focused on developing next-generation antibody-drug conjugates to enhance cancer treatment. Webcasts of select events will be available on their website.
Read more →STROSutro Biopharma Announces Participation at the 16th World ADC London Summit
Sutro Biopharma, a clinical-stage oncology company, announced its participation in the 16th World ADC London Summit from February 23-26, 2026. The event will feature discussions on their innovative antibody-drug conjugate platform, which aims to enhance cancer treatment options. Following the summit, content from the plenary session will be available on Sutro's website.
Read more →STRO▲ +11.9%on this news
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
Sutro Biopharma has announced the pricing of an underwritten offering of 7,868,383 shares at $13.98 each, aiming to raise approximately $110 million. The offering is set to close on February 11, 2026, and will support various corporate purposes, including funding research and development of its antibody-drug conjugates. The offering has attracted participation from several notable investors.
Read more →STRO▲ +11.9%on this newsshared move
February 2026 NASDAQ: STRO Forward-Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions and on inform
Sutro Biopharma has released forward-looking statements outlining its development pipeline and anticipated financial performance. The company emphasizes its proprietary platform for enhanced antibody-drug conjugates (ADCs), targeting unmet needs in oncology. Several candidates are advancing toward investigational new drug (IND) submissions in 2026, backed by a solid financial runway until at least mid-2028. However, there are inherent risks related to regulatory decisions and market competition that may impact future outcomes.
Read more →STROSutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sutro Biopharma, a clinical-stage oncology company focused on novel antibody drug conjugates, announced that CEO Jane Chung will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. This presentation highlights Sutro's advancements in cancer treatment through their unique ADC platform. A live webcast of the event will be available, along with an archived replay post-event.
Read more →STROSutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Sutro Biopharma has successfully regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split. As of December 16, 2025, the company's stock price averaged over $1.00, allowing it to meet the necessary listing standards. This development is significant for Sutro as it continues to advance its innovative cancer therapies.
Read more →STROSutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sutro Biopharma announced the granting of stock options and restricted stock units to new non-executive employees as part of their employment agreement. This decision was made in accordance with Nasdaq Listing Rule 5635(c)(4) to induce the acceptance of roles within the company. The compensation plan highlights Sutro's commitment to expanding its workforce while pursuing innovative cancer therapies through its ADC platform.
Read more →STRO▲ +19.2%on this news
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
Sutro Biopharma has initiated dosing in the first cohort of its Phase 1 trial for STRO-004, targeting Tissue Factor-expressing solid tumors. The trial aims to evaluate safety and preliminary anti-tumor activity, with initial data expected in mid-2026. STRO-004 is designed to improve drug exposure and reduce side effects compared to existing therapies.
Read more →STRO▼ -12.8%on this newsshared move
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
Sutro Biopharma has announced a 1-for-10 reverse stock split effective December 3, 2025, to comply with Nasdaq's minimum bid price requirement. This decision was approved by stockholders during the 2025 annual meeting. The split will reduce the number of outstanding shares while maintaining stockholder ownership percentages, and adjustments will be made to equity awards accordingly.
Read more →STROSociety for Immunotherapy of Cancer (SITC) 2025 Annual Meeting – Poster Presentation
The Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting will feature a presentation on next-generation immunostimulatory antibody-drug conjugates (iADCs). These iADCs aim to combine tumor cell killing with immune activation, potentially leading to durable antitumor immunity. The presentation can be accessed through a provided link.
Read more →STRO16th Annual World ADC San Diego – Presentations
The 16th Annual World ADC Conference in San Diego featured several presentations on advancements in antibody-drug conjugates (ADCs). Notable topics included the development of high-DAR dual-payload ADCs, immunostimulatory ADCs, and strategies to enhance therapeutic indices. Researchers presented their findings on overcoming resistance mechanisms and improving supply chain efficiencies in ADC manufacturing.
Read more →STROSutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
Sutro Biopharma hosted a virtual R&D Day to showcase its innovative ADC pipeline, including the initiation of a Phase 1 study for STRO-004, a Tissue Factor ADC. The company also introduced STRO-227, its first dual-payload candidate targeting PTK7. Sutro aims to address difficult-to-treat solid tumors and improve cancer care through its unique platform technology.
Read more →STROSutro R&D Day – Presentation
Sutro Biopharma held a Research and Development Day, presenting key updates on their pipeline and future projects. The event included a webcast for broader engagement with stakeholders. The company aims to enhance transparency and communication regarding their innovative therapies. A presentation deck is available for further details.
Read more →About Sutro Biopharma, Inc.
Headquarters111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next STRO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime